



HUTCHISON CHINA MEDITECH LTD

For Immediate Release

19th May 2006

Hutchison China MediTech Limited ("Chi-Med")

First day of dealings on AIM

Chi-Med announces that admission to trading on AIM will become effective, and dealings in the ordinary shares of the Company will start, at 8.00am today, 19th May 2006, under the ticker symbol "HCM". The ISIN number will be KYG4672N1016. Dealings will be conducted in CREST through Depository Interests each representing an interest in one ordinary share.

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine ("TCM") and botanical ingredients. Chi-Med's overall aim is to draw on the untapped wealth of knowledge and history of usage in the TCM industry to develop pharmaceutical and consumer products for the global market.

On 10th May 2006, Chi-Med announced that it will have raised gross proceeds of approximately £40 million through a placing with institutional and other qualified investors and via a Hong Kong Preferential Offering to qualifying shareholders of Hutchison Whampoa Limited of a total of 14,545,454 new shares at a price of 275 pence per ordinary share (the "Placing Price"). Based on that Placing Price, the market capitalisation of Chi-Med on admission will be approximately £141 million.

Lazard & Co., Limited is Nominated Advisor to Chi-Med and Panmure Gordon are Brokers to the Placing.

Contacts

Lazard & Co., Limited
Paul Gismondi
Peter Coupe
Tel: +44 (0) 20 7187 2000

Panmure Gordon
Richard Gray
Gilbert Ellacombe
Tel: +44 (0) 20 7459 3600

Citigate Dewe Rogerson
Anthony Carlisle (Mobile: + 44 (0) 7973 611 888)
Chris Gardner
Sarah Gestetner
Tel: +44 (0) 20 7638 9571

Lazard & Co., Limited ("Lazard") of 50 Stratton Street, London W1J 8LL, is acting exclusively for Chi-Med and no-one else in connection with Admission and the Placing and will not be responsible to anyone other

than Chi-Med for providing the protections afforded to the clients of Lazard, nor for providing advice in relation to Admission or the Placing, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

Panmure Gordon (Broking) Limited ("Panmure Gordon"), of 155 Moorgate, London EC2M 6XB, is acting exclusively for Chi-Med and no-one else in connection with the Placing and will not be responsible to anyone other than Chi-Med for providing the protections afforded to the clients of Panmure Gordon, nor for providing advice in relation to the Placing, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

This announcement does not constitute an offer of, or the solicitation of an offer to buy or subscribe for, Ordinary Shares to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful and, in particular, is not for release, publication or distribution in or into Australia, Canada, Japan, The Republic of Ireland, The Republic of South Africa, the Cayman Islands or the United States.

The offer and sale of the ordinary shares has not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of Australia, Canada, Japan, The Republic of Ireland, The Republic of South Africa or the Cayman Islands. Subject to certain exceptions, the ordinary shares may not be offered or sold in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa, the Cayman Islands or the United States.